If I’d invested £5k in GSK shares one year ago here’s what I’d have today

GSK shares have disappointed lately, but today’s low valuation and rising yield could make now the perfect time to buy.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Young Black woman looking concerned while in front of her laptop

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GSK (LSE: GSK) shares haven’t done much since it spun off its consumer healthcare business Haleon last July. I see this as an opportunity to buy the FTSE 100 pharmaceutical stock at an attractive price, then hold on for the recovery.

In its halcyon days as GlaxoSmithKline, this was arguably the most popular dividend stock on the entire index, reliably yielding 5% or 6% a year. It lost that mantle as CEO Emma Walmsley froze the dividend at 80p for years, diverting the company’s cash into R&D rather than shareholders’ pockets. The Glaxo share price drifted lower, and income investors drifted away.

I’m after income and growth

GSK reported a positive 2022 with sales up 19% to £29.3bn, while generating free cash flow of £3.3bn. Last month’s Q1 profits and revenues also beat expectations at £7bn and £2.1bn respectively, boosted by successful shingles and meningitis treatments.

Yet the share price remains sluggish. It’s up just 2.16% over the last three months. Over one year, it’s down 16.12% to 1,475p per share. That compares to growth of 4.17% across the FTSE 100 as a whole.

If I had invested £5,000 in GSK shares one year ago, as I was tempted to do, I would have just £4,194 today, a loss of £806.

In practice, I would have slightly more, thanks to the dividend. A year ago, £5k would have bought around 272 shares at 1,839p each. The 2022 dividend of 44p per share would be worth around £120, lifting my stake to £4,314. I’d still be down £686 though.

So what does the future hold and should I invest £5,000 in GSK today?

Walmsley has been holding out the promise of a steadily flowing drugs pipeline for some years now, but there are signs she will finally deliver. At last count, the firm had 69 vaccines and speciality medicines in various states of progress.

Getting drugs approved is a long and uncertain process, and no doubt there will be plenty of slips and setbacks along the way. If the pipeline doesn’t flow as hoped, the GSK share price may continue to underwhelm.

I’m in it for the long term

As a private investor, it’s impossible for me to have a clear view of GSK’s chances of success, but I have one thing in my favour. Time.

I would only buy a stock like this with a five- or 10-year view, which should give plenty of scope for its raft of treatments to build.

In the interim, there’s the dividend. Currently, the yield is disappointing at 3%, below the FTSE 100 average of 3.5%. Yet it’s covered 3.2 times by earnings, giving scope for progression. Better still, it’s forecast to hit 3.8% this year, and should still be covered 2.6 times. With luck, it should climb higher over time, although, as ever with dividends, there are no guarantees.

GSK’s operating margins are forecast to climb from 21.9% to 28.5%, while management predicts adjusted operating profit will rise between 10% and 12%.

I don’t directly hold any pharmaceutical stocks, and would like to change that. Today’s low valuation of 10.5 times earnings looks like a good entry point. Hopefully, GSK will begin to deliver more growth and income than it did over the last 12 months.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones has no position in any of the shares mentioned. The Motley Fool UK has recommended GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Prediction: these FTSE 100 stocks could be among 2025’s big winners

Picking the coming year's FTSE 100 winners isn't an easy task, but we're all thinking about it at this time…

Read more »

Investing Articles

This UK dividend share is currently yielding 8.1%!

Our writer’s been looking at a FTSE 250 dividend share that -- due to its impressive 8%+ yield -- is…

Read more »

Investing Articles

If an investor put £10,000 in Aviva shares, how much income would they get?

Aviva shares have had a solid run, and the FTSE 100 insurer has paid investors bags of dividends too. How…

Read more »

Investing Articles

Here’s why I’m still holding out for a Rolls-Royce share price dip

The Rolls-Royce share price shows no sign of falling yet, but I'm still hoping it's one I can buy on…

Read more »

Investing Articles

Greggs shares became 23% cheaper this week! Is it time for me to take advantage?

On the day the baker released its latest trading update, the price of Greggs shares tanked 15.8%. But could this…

Read more »

Investing Articles

Down 33% in 2024 — can the UK’s 2 worst blue-chips smash the stock market this year?

Harvey Jones takes a look at the two worst-performing shares on the FTSE 100 over the last 12 months. Could…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

Are National Grid shares all they’re cracked up to be?

Investors seem to love National Grid shares but Harvey Jones wonders if they’re making a clear-headed assessment of the risks…

Read more »

Investing For Beginners

Here’s what the crazy moves in the bond market could mean for UK shares

Jon Smith explains what rising UK Government bond yields signify for investors and talks about what could happen for UK…

Read more »